The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
-
COMMENTARY Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
REGULATORY CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
-
REGULATORY Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
-
BUSINESS ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
-
REGULATORY LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
-
BUSINESS Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
-
REGULATORY PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
-
BUSINESS Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
-
BUSINESS LEO Pharma Japan Set to Follow Global Growth as Stand-Alone Sales Force Matures
December 9, 2024
-
ACADEMIA Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
-
BUSINESS First Generics of Equa Priced at 30% of Original Product
December 6, 2024
-
REGULATORY Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
-
REGULATORY DPP Submits Request to MOF for Scrapping Off-Year Revisions
December 5, 2024
-
REGULATORY (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
-
REGULATORY Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
-
REGULATORY LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
-
BUSINESS Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
-
REGULATORY Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…